Musely taps General Catalyst fund to fuel non-dilutive growth

Musely raised $360 million from General Catalyst without giving up equity, a financing choice that says as much about the venture market as it does about the telehealth company’s growth. The money is aimed at customer acquisition, the costliest part of scaling a consumer health brand, and it comes with a tradeoff that is easy to miss in the phrase non-dilutive.

Musely sells prescription tele-dermatology treatments for skin, hair, body and private-area care, menopause, and longevity concerns. The company says its FaceRx telemedicine platform launched in 2019 and has since expanded from two treatments to 24. A September 2024 company release said Musely had grown 100-fold, reached nine-figure revenue, turned profitable, and dispensed millions of unique prescription treatments. Musely also says it serves more than 1,000,000 real patients, and some products carry a $20 online doctor-visit fee.

General Catalyst built its Customer Value Fund for exactly this kind of business. KV Mohan, who co-heads the fund, has said the strategy is designed to finance sales and marketing for companies that already have product-market fit, allowing them to grow without repeated equity rounds. That matters because each new financing can dilute founders and early investors. In this structure, the dilution is avoided, but the capital still has to be repaid, usually from the revenue it helps generate. If growth underperforms, the pressure shifts from ownership to cash flow.

That makes the deal less a victory lap than a test of business quality. Musely’s profitability, nine-figure revenue and million-plus customer base suggest a company with enough scale to justify a revenue-linked financing package. It also helps that the brand has broadened beyond acne and anti-aging into a wider set of recurring, prescription-driven categories where patients may return for follow-on treatment.

The Musely transaction follows the same pattern General Catalyst used in 2025 for Grammarly, which said it raised $1 billion in non-dilutive financing and would repay the capital from revenue rather than equity. The model is attractive in a market where growth companies want capital for marketing but are wary of constant down rounds and dilution. It is also demanding: the company has to keep converting that spending into durable revenue fast enough to service the capital.

For Musely, the bet is that customer acquisition can still scale efficiently in a crowded digital health market. For General Catalyst, the wager is that product-market fit and strong unit economics can make non-dilutive capital look less like debt and more like an alternative path through a tight venture cycle.